Published in Am J Gastroenterol on June 01, 2002
The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology (2011) 2.18
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis (2004) 1.80
Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol (2007) 1.32
Retracted Biologic targeting in the treatment of inflammatory bowel diseases. Biologics (2009) 1.20
Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol (2010) 1.06
Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol (2009) 0.96
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World J Gastroenterol (2010) 0.91
Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol (2011) 0.86
Serological markers of inflammatory bowel disease. Biochem Med (Zagreb) (2013) 0.83
Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol (2003) 0.81
Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem (2014) 0.78
Interleukin-18 is increased only in a minority of patients with active Crohn's disease. Int J Colorectal Dis (2007) 0.77
Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies. Sci Rep (2015) 0.77
New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.77
IFNG rs1861494 polymorphism is associated with IBD disease severity and functional changes in both IFNG methylation and protein secretion. Inflamm Bowel Dis (2014) 0.75
Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol (2016) 0.75
Clinical and genetic factors predicting response to therapy in patients with Crohn's disease. United European Gastroenterol J (2014) 0.75
Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci (2017) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut (2006) 8.08
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Aligning conservation priorities across taxa in Madagascar with high-resolution planning tools. Science (2008) 5.07
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet (1996) 4.09
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther (2012) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther (2012) 2.74
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut (1984) 2.70
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Current status of genetics research in inflammatory bowel disease. Genes Immun (2005) 2.29
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy (2006) 2.24
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol (1998) 2.20
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology (1997) 2.18
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
Predicting relapse in Crohn's disease: a biopsychosocial model. Gut (2008) 2.01
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Automated neonatal seizure detection mimicking a human observer reading EEG. Clin Neurophysiol (2008) 1.96
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
Effect of a 2 g cimetidine infusion on twenty-four-hour intragastric pH in critically ill patients. Intensive Care Med (1988) 1.95
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
Spontaneous secretion of interferon gamma and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut (1998) 1.88
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol (1997) 1.85
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
Antigenic variability of Candida albicans. Crit Rev Microbiol (1985) 1.79
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol (2001) 1.72
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut (2003) 1.66
Histopathology of intestinal inflammation related to reactive arthritis. Gut (1987) 1.64
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol (1998) 1.60
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc (1999) 1.59
Home parenteral nutrition in adults: a multicentre survey in Europe in 1993. Clin Nutr (1996) 1.58
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. Eur J Nucl Med (1998) 1.56
Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut (1999) 1.55
Validation of a new automated neonatal seizure detection system: a clinician's perspective. Clin Neurophysiol (2011) 1.52
Mapping of Candida albicans oligomannosidic epitopes by using monoclonal antibodies. Infect Immun (1992) 1.52
Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology (1997) 1.52
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50